Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer

OBJECTIVES: In randomized-controlled crossover design trials, overall survival (OS) treatment effect estimates are often confounded by the control group benefiting from treatment received post-progression. We estimated the adjusted OS treatment effect in EMPOWER-Lung 1 (NCT03088540) by accounting fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Feliciano, Josephine Louella, McLoone, Dylan, Xu, Yingxin, Quek, Ruben G.W., Kuznik, Andreas, Pouliot, Jean-Francois, Gullo, Giuseppe, Rietschel, Petra, Guyot, Patricia, Konidaris, Gerasimos, Chan, Keith, Keeping, Sam, Wilson, Florence R., Freemantle, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110970/
https://www.ncbi.nlm.nih.gov/pubmed/37082098
http://dx.doi.org/10.3389/fonc.2022.1081729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110970/
https://www.ncbi.nlm.nih.gov/pubmed/37082098
http://dx.doi.org/10.3389/fonc.2022.1081729

Ejemplares similares